XTL6001 / Shaanxi Micot Technology - LARVOL DELTA

XTL6001: a novel triple MasR/GCGR/GLP-1R agonist for chronic kidney disease/diabetic kidney disease with proteinuria and hyperuricaemia (EASD 2026) - P1 | "Within the tested dose range, the 24-hour urinary albumin reduction rates of XTL6001 were 55.85% to 81.85% (vs. 38.64% for Finerenone) in Model 1, 54.72% (vs. 32.49% for Finerenone combined with Dulaglutide) in Model 2, and 71.44% to 86.26% in Model 3 (uric acid-lowering medication benzbromarone had no effect on reducing urinary albumin), respectively. These findings indicated XTL6001 offers a multidimensional therapeutic solution for patients with CKD/DKD complicated by proteinuria and hyperuricemia by integrating renal protection and metabolic regulation. Thus, XTL6001 warrant further clinical assessment."

Metabolic Disorders

XTL6001: a novel triple MasR/GCGR/GLP-1R agonist for weight loss and obesity-related complications (EASD 2026) - P1 | "These findings indicate XTL6001 confers superior improvements in body weight loss and obesity complications with good safety and tolerability and warrant further clinical assessment."

First-in-human • Metabolic Disorders • Obesity

XTL6001: A Novel Triple MasR/GCGR/GLP-1R Agonist for Weight Loss and Obesity-Related Complications (ADA 2026) - P1 | "These findings indicate XTL6001 confers superior improvements in body weight loss and obesity complications with good safety and tolerability and warrant further clinical assessment."

First-in-human • Metabolic Disorders • Obesity

XTL6001: A Novel Triple MasR/GCGR/GLP-1R Agonist for Chronic Kidney Disease/Diabetic Kidney Disease with Proteinuria and Hyperuricemia (ADA 2026) - "Within the tested dose range, the 24-hour urinary albumin reduction rates of XTL6001 were 55.85% to 81.85% (vs. 38.64% for Finerenone) in Model 1, 54.72% (vs. 32.49% for Finerenone combined with Dulaglutide) in Model 2, and 71.44% to 86.26% in Model 3 (uric acid-lowering medication benzbromarone had no effect on reducing urinary albumin), respectively. These findings indicated XTL6001 offers a multidimensional therapeutic solution for patients with CKD/DKD complicated by proteinuria and hyperuricemia by integrating renal protection and metabolic regulation. Thus, XTL6001 warrant further clinical assessment."

Metabolic Disorders

Phase I Study of XTL6001 Injection in Healthy and Obese Subjects (clinicaltrials.gov) - P1 | N=80 | Recruiting | Sponsor: Shanghai Xitaili Biomedicine Technology co., Ltd.

New P1 trial • Genetic Disorders • Obesity